All In Biotech

Free tool

FAERS Monitor: Lotensin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019851 or its brand name (Lotensin, Benazepril Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

7,351

Serious

4,638

63% of reports

Hospitalization

2,498

Death reported

582

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea454
  • drug ineffective431
  • fatigue414
  • dizziness401
  • dyspnoea387
  • diarrhoea367
  • pain365
  • headache357
  • myocardial infarction311
  • hypertension303
  • asthenia274
  • cough266
  • vomiting263
  • anxiety253
  • cerebrovascular accident250

Reports by year received

View as table
YearReports
2004305
2005352
2006419
2007320
2008327
2009511
2010637
2011699
2012537
2013191
2014406
2015288
2016278
2017311
2018266
2019193
2020130
2021151
2022210
2023175
2024193
2025168
2026283

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,808 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myocardial infarctionSignal3115.14.61,030
cerebrovascular accidentSignal2504.23.7617
hypertensionSignal3034.13.7713
coughSignal2662.72.4290
anxietySignal2532.52.3239
dizzinessSignal4012.32.1301
astheniaSignal2742.11.9156
dyspnoea3872.01.8185
pain3651.71.5108
nausea4541.61.5118
headache3571.61.589
diarrhoea3671.61.591
vomiting2631.61.460
fatigue4141.51.476
drug ineffective4310.90.92

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.